Enbrel Growth Plans Include Copay Assistance, DTC
This article was originally published in The Pink Sheet Daily
Executive Summary
Market share has stabilized but Amgen acknowledges that the TNF inhibitor “isn’t performing up to our expectations.”
You may also be interested in...
Amgen Will Have Day In Court With Roche
The company also reports that sales of its TNF inhibitor Enbrel are “not meeting expectations.”
Amgen Will Have Day In Court With Roche
The company also reports that sales of its TNF inhibitor Enbrel are “not meeting expectations.”
TAP’s Prevacid PAP Is Available To Part D Beneficiaries; Bristol-Myers Squibb To Focus On Coalition Approach
TAP extended its Prevacid prescription assistant program to Medicare drug plan enrollees whose household income is between 135% and 200% of the federal poverty level.